Saturday 17 October 2026
Export GYRE’s income statement to Excel — free account
Gyre Therapeutics, Inc.
GYRE Healthcare Biotechnology
In the quarter to June 2026, revenue fell 2.12%, EPS was flat and free cash flow fell 130.5%, each against the same quarter a year earlier.
6.08
0.32
−5.00%
Follow GYRE
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
5 | 4 | 5 | 2 |
| 3.53% | 6.37% | (5.27%) | (11.75%) | ||
| 2.93% | 2.91% | (4.36%) | (9.08%) | ||
ROIC |
6.16% | 7.50% | (0.10%) | (8.51%) | |
Return on Tangible Assets |
3.92% | 3.28% | (6.66%) | (13.24%) | |
Average Days of Receivables |
86.45 | 98.02 | 71.70 | 87.83 | |
Free Cash Flow per Share |
0.02 | (0.01) | 0.03 | (0.07) | |
Free Cash Flow |
1.51 | (0.88) | 3.07 | (7.12) | |
Capital Expenditures |
(2.37) | (1.89) | (1.25) | (2.19) | |
| Other line items | |||||
Cash ROIC |
0.76% | (0.31%) | 1.64% | (2.97%) | |
Accounts Receivable Turnover |
4.70 | 4.16 | 5.40 | 4.40 | |
Accounts Payable Turnover |
11.29 | 7.51 | 29.71 | 10.42 | |
Inventory Turnover |
0.64 | 0.66 | 0.60 | 0.67 | |
Average Days of Payables |
41.84 | 89.97 | 16.82 | 66.28 | |
Days of Inventory on Hand |
666.33 | 685.45 | 720.73 | 612.78 | |
Tax Rate |
(0.30) | (0.32) | (7.58) | 0.28 | |
Research and Development Expense of Revenue |
15.90% | 11.75% | 14.82% | 24.16% | |
Selling, General and Administrative Expense of Revenue |
72.79% | 73.75% | 78.21% | 77.90% | |
Share Based Compensation of Revenue |
2.84% | 6.14% | 7.89% | 8.48% | |
Interest Coverage |
— | — | — | (6.52) | |
Operating CF/Net income |
0.93 | 0.20 | (0.68) | 0.31 | |
Depreciation/Fixed assets |
0.10 | 0.09 | 0.11 | 0.12 | |
Capex/Depreciation |
(1.02) | (0.75) | (0.47) | (0.69) | |
Revenue per Share |
1.21 | 1.30 | 1.28 | 1.16 | |
Operating CF per Share |
0.04 | 0.01 | 0.05 | (0.05) | |
Capex per Share |
(0.03) | (0.02) | (0.01) | (0.02) | |
Capex to Sales |
0.02 | 0.02 | 0.01 | 0.02 |
Columns are period end dates